RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in the United States [Meeting abstract PIN19]
Davis, A. E., Brogan, A., & Goodwin, BB. (2016). Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in the United States [Meeting abstract PIN19]. Value in Health, 19(3), A214-A215. https://doi.org/10.1016/j.jval.2016.03.1207
RAL has the lowest per-person cost compared with two other common first-line regimens, DRV/r and ATV/r, each used in combination with TDF/FTC, for treatment-naive adults with HIV-1 infection in the US. These results were found to be robust in sensitivity and scenario analyses. This economic evidence further complements the known clinical benefits of RAL as reported in the ACTG 5257 clinical trial.